Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate if concentration of tacrolimus metabolites is increased in patients presenting tacrolimus (TAC) side effects.


Clinical Trial Description

The study will evaluate whether the blood concentration of TAC metabolites (13-O-desmethyl-tacrolimus, 15-O-desmethyl-tacrolimus and 31-O-desmethyl-tacrolimus), measured between Day1 and Day5 of its introduction, is increased in patients with TAC toxicity. A blood test will be performed daily from Day1 to Day5 for the measurement of TAC concentration and TAC metabolites concentration. ;


Study Design


NCT number NCT05277792
Study type Observational
Source Rennes University Hospital
Contact Michel RAYAR, MD-PhD
Phone 299288498
Email michel.rayar@chu-rennes.fr
Status Recruiting
Phase
Start date May 8, 2022
Completion date June 8, 2024